Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-033 MAD Study in Healthy Adult Participants
NCT07619183Phase 1Not yet recruiting
- Sponsor
- Prime Gene Therapeutics
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lichen simplex chronicus (LSC) comparing Multiple Ascending Doses of PG-033 tablets with Placebo (2 arms). Primary endpoint: Safety and tolerability of PG-033 tablets at 17 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
PG-033
03
Conditions
lichen simplex chronicus (LSC)
Beyond the preview
Go deeper on NCT07619183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619183.